gvtcx

Purchase of DPYD (dihydropyrimidine dehydrogenase) testing kits

key details

Statuscomplete
Category (CPV) 33696500
RegionWales
Procedurelimited
OCIDocds-h6vhtk-02bcb3

Award

SupplierValueDateStatus
Yourgene Health · · active

description

All Wales Genomics Laboratory (AWMGL) has been providing testing for DPYD (dihydropyrimidine dehydrogenase) deficiency since July 2020. Germline variants in the DPYD gene can confer an increased risk of severe or fatal toxicity for cancer patients being treated with common fluoropyrimidine based chemotherapies, 5-fluoruracil and/or capecitabine. Therefore results allow clinicians to assess if the treatment is suitable for the patient.

Due to considerable increase in the demand for the test the AWMGL intends to award a two year contract (for a period of 12 months with the option to extend for a further 12 months) to ensure continuity of service to the patients of NHS Wales.

notice history

1 notice published against this procurement.

PublishedTypeRegimeNotice
16 Jun 2021 Voluntary ex-ante transparency (F15) Earlier regulations 013632-2021

more from NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Find a Tender. Contact details for named individuals are not reproduced on this site.